March 2020 PMID 31880325

The creatine kinase conundrum: a reappraisal of the association of isotretinoin, creatine kinase, and rhabdomyolysis.

Justin W Marson, Hilary E Baldwin

Download social card

Mentions

3
Peak: 1 in Jun 2021
across 2 sources since Jun 2021

Extended reach

35,646
potential audience

Total likes

258

Video views

21,539

Mentions per month

Jun 2021 – Apr 2023

Where it's discussed

  • X / Twitter2 posts
  • YouTube1 videos

AI synopsis

What people are saying

The overall tone indicates consensus that monitoring of creatine kinase in patients on isotretinoin is rarely performed because the risk of rhabdomyolysis is considered very low, as shown by phrases like 'stress/cost of false positives' and 'unlikely to influence management.' The language is cautious and pragmatic, reflecting clinical conservatism rather than excitement or controversy.

AgreementModerate agreement

Most discussions agree that there are no current guidelines for monitoring creatine kinase and that rhabdomyolysis is rare, leading to a mild overall consensus.

InterestNeutral interest

The posts show neutral engagement with the topic, primarily agreeing with the idea rather than exploring new angles.

EngagementNeutral engagement

The comments are somewhat superficial, mainly expressing opinions without delving into deeper implications or details from the research.

ImpactNeutral impact

The conversations suggest limited influence on practice or policy changes, as they reflect on existing clinical considerations rather than proposing alterations.

Abstract in brief

  • Isotretinoin can increase creatine kinase levels, raising concerns for serious conditions like rhabdomyolysis.
  • Elevated creatine kinase may be influenced by factors such as skin type and gender, with darker-skinned individuals and males being more susceptible.
  • While there’s a link between isotretinoin, increased creatine kinase, and exercise, doctors should monitor athletes' CK levels but shouldn’t necessarily discourage isotretinoin use based on this risk.

Top posts

Most liked on X and Bluesky
John Barbieri, MD, MBA
@DrJohnBarbieri · X

There are currently no guidelines for monitoring CPK. However, I do not routinely check given stress/cost of false positives and since unlikely to change management due to rhabdomyolysis being exceedingly rare. Consider checking if severe myalgias 11/13 https://t.co/RaB3vwRvXe

Jul 13, 2021 · 3 likes · 7,054 followers View post →
John Barbieri, MD, MBA
@DrJohnBarbieri · X

There are currently no guidelines for monitoring CPK. However, I do not routinely check given stress/cost of false positives and since unlikely to influence management due to rhabdomyolysis being exceedingly rare. Consider checking if severe myalgias 11/x https://t.co/RaB3vwRvXe

Jun 9, 2021 · 2 likes · 7,054 followers View post →

All mentions

John Barbieri, MD, MBA
@DrJohnBarbieri · X

There are currently no guidelines for monitoring CPK. However, I do not routinely check given stress/cost of false positives and since unlikely to change management due to rhabdomyolysis being exceedingly rare. Consider checking if severe myalgias 11/13 https://t.co/RaB3vwRvXe

Jul 13, 2021 · 3 likes · 7,054 followers View post →
John Barbieri, MD, MBA
@DrJohnBarbieri · X

There are currently no guidelines for monitoring CPK. However, I do not routinely check given stress/cost of false positives and since unlikely to influence management due to rhabdomyolysis being exceedingly rare. Consider checking if severe myalgias 11/x https://t.co/RaB3vwRvXe

Jun 9, 2021 · 2 likes · 7,054 followers View post →